Immutep Ltd Sponsored ADR Stock

$2.05

1.91% yesterday

Nasdaq, Nov 15, 10:00 pm CET

ISIN

US45257L1089

Symbol

IMMP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Immutep Ltd Sponsored ADR Stock price

$2.05

+0.24 13.53% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.04 1.91%

ISIN

US45257L1089

Symbol

IMMP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$298.19m
Enterprise Value	$177.78m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	2.35
Revenue growth (TTM) Revenue growth	-100.00%
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-33.03m
Free Cash Flow (TTM) Free Cash Flow	$-22.94m
EPS (TTM) EPS	$-0.23
P/E forward	negative
P/S forward	90.65
EV/Sales forward	54.75
Short interest	3.51%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Immutep Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

7x Buy

100%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Immutep Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	1.48 1.48	18% 18% -
Gross Profit	-1.48 -1.48	18% 18% -
- Selling and Administrative Expenses	30 30	8% 8% -
- Research and Development Expense	- -	- -
EBITDA	-32 -32	9% 9% -
- Depreciation and Amortization	1.48 1.48	18% 18% -
EBIT (Operating Income) EBIT	-33 -33	9% 9% -
Net Profit	-28 -28	4% 4% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Immutep Ltd Sponsored ADR Stock News

Positive

Seeking Alpha

●

about 6 hours ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is pr...

Neutral

GlobeNewsWire

●

one day ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0% Data from all evaluable patients to date (N=40) demonstrates significant improvement...

Neutral

GlobeNewsWire

●

18 days ago

Immutep Quarterly Activities Report Q1 FY25

SYDNEY, AUSTRALIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 September 2024 (Q1 FY25).

More Immutep Ltd Sponsored ADR News

Company Profile

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Head office	Australia
CEO	Marc Voigt
Founded	1987
Website	www.immutep.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now